ORKA insider trading — Oruka Therapeutics, Inc.
Over the last 90 days, insiders at Oruka Therapeutics, Inc. (ORKA) made 0 open-market purchases worth $0 and 3 open-market sales worth $421K, making them net sellers by $421K. The largest sale was by Klein Lawrence Otto (Chief Executive Officer), who sold 2,452 shares for $235K on Sep 15, 2026.
Updated Oct 16, 2026.
Recent ORKA insider transactions
Every Form 4 filed by Oruka Therapeutics, Inc. officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | Goncalves Joana | Chief Medical Officer | M · Option exercise · 10b5-1 | Direct | 7,000 | $7.32 | $51K | Form 4 |
| Oct 15, 2026 | Goncalves Joana | Chief Medical Officer | S · Sale · 10b5-1 | Direct | 7,000 | $74.81 | $524K | Form 4 |
| Oct 12, 2026 | Agarwal Arjun | Senior Vice President, Finance | M · Option exercise · 10b5-1 | Direct | 9,999 | $15.69 | $157K | Form 4 |
| Oct 12, 2026 | Agarwal Arjun | Senior Vice President, Finance | S · Sale · 10b5-1 | Direct | 9,999 | $80.60 | $806K | Form 4 |
| Oct 1, 2026 | Klein Lawrence Otto | Chief Executive Officer | M · Option exercise · 10b5-1 | Direct | 25,000 | $7.80 | $195K | Form 4 |
| Oct 1, 2026 | Klein Lawrence Otto | Chief Executive Officer | S · Sale · 10b5-1 | Direct | 25,000 | $83.62 | $2.09M | Form 4 |
| Sep 21, 2026 | Agarwal Arjun | Senior Vice President, Finance | S · Sale · 10b5-1 | Direct | 533 | $95.75 | $51K | Form 4 |
| Sep 21, 2026 | Quinlan Paul T | General Counsel | M · Option exercise · 10b5-1 | Direct | 10,000 | $7.80 | $78K | Form 4 |
| Sep 21, 2026 | Quinlan Paul T | General Counsel | S · Sale · 10b5-1 | Direct | 10,000 | $93.64 | $936K | Form 4 |
| Sep 15, 2026 | Goncalves Joana | Chief Medical Officer | M · Option exercise · 10b5-1 | Direct | 7,000 | $7.32 | $51K | Form 4 |
| Sep 15, 2026 | Goncalves Joana | Chief Medical Officer | S · Sale · 10b5-1 | Direct | 7,947 | $92.38 | $734K | Form 4 |
| Sep 15, 2026 | Agarwal Arjun | Senior Vice President, Finance | S · Sale · 10b5-1 | Direct | 560 | $95.71 | $54K | Form 4 |
| Sep 11, 2026 | Agarwal Arjun | Senior Vice President, Finance | M · Option exercise · 10b5-1 | Direct | 9,459 | $15.88 | $150K | Form 4 |
| Sep 11, 2026 | Agarwal Arjun | Senior Vice President, Finance | S · Sale · 10b5-1 | Direct | 9,459 | $92.23 | $872K | Form 4 |
| Sep 15, 2026 | Klein Lawrence Otto | Chief Executive Officer | S · Sale | Direct | 2,452 | $95.71 | $235K | Form 4 |
| Sep 15, 2026 | Quinlan Paul T | General Counsel | S · Sale | Direct | 1,039 | $95.71 | $99K | Form 4 |
| Sep 15, 2026 | Sandler Laura Lee | Chief Operating Officer | S · Sale | Direct | 906 | $95.71 | $87K | Form 4 |
| Sep 1, 2026 | Sandler Laura Lee | Chief Operating Officer | M · Option exercise · 10b5-1 | Direct | 5,000 | $7.80 | $39K | Form 4 |
| Sep 1, 2026 | Sandler Laura Lee | Chief Operating Officer | S · Sale · 10b5-1 | Direct | 5,000 | $91.82 | $459K | Form 4 |
| Sep 1, 2026 | Klein Lawrence Otto | Chief Executive Officer | M · Option exercise · 10b5-1 | Direct | 75,000 | $7.80 | $585K | Form 4 |
| Sep 1, 2026 | Klein Lawrence Otto | Chief Executive Officer | S · Sale · 10b5-1 | Direct | 75,000 | $91.83 | $6.89M | Form 4 |
| Aug 24, 2026 | Edwards Larry Todd | Chief Commercial Officer | A · Grant/award | Direct | 100,000 | — | — | Form 4 |
| Aug 17, 2026 | Goncalves Joana | Chief Medical Officer | M · Option exercise · 10b5-1 | Direct | 7,000 | $7.32 | $51K | Form 4 |
| Aug 17, 2026 | Goncalves Joana | Chief Medical Officer | S · Sale · 10b5-1 | Direct | 7,000 | $111.84 | $783K | Form 4 |
| Aug 14, 2026 | Quinlan Paul T | General Counsel | M · Option exercise · 10b5-1 | Direct | 52,000 | $11.60 | $603K | Form 4 |
| Aug 14, 2026 | Quinlan Paul T | General Counsel | S · Sale · 10b5-1 | Direct | 52,000 | $108.49 | $5.64M | Form 4 |
| Aug 13, 2026 | Agarwal Arjun | Senior Vice President, Finance | M · Option exercise · 10b5-1 | Direct | 10,000 | $15.69 | $157K | Form 4 |
| Aug 13, 2026 | Agarwal Arjun | Senior Vice President, Finance | S · Sale · 10b5-1 | Direct | 10,000 | $106.66 | $1.07M | Form 4 |
ORKA insider trading FAQ
Are insiders buying ORKA stock?
Not on the open market. In the last 90 days, Oruka Therapeutics, Inc. insiders made no open-market purchases, and 3 open-market sales totaling $421K. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading ORKA?
Recent sellers: Klein Lawrence Otto, Quinlan Paul T, Sandler Laura Lee.
Where does ORKA insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.